CoChat

Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model

Doisy, Mathilde, Vacca, Ophélie, Fergus, Claire, Gileadi, Talia, Verhaeg, Minou, Saoudi, Amel, Tensorer, Thomas, Garcia, Luis, Kelly, Vincent P., Montanaro, Federica, Morgan, Jennifer E., van Putten, Maaike, Aartsma-Rus, Annemieke, Vaillend, Cyrille, Muntoni, Francesco, Goyenvalle, Aurélie · 2023 · Biomedicines
Cited by 13

The DOI matches its Crossref record.

Abstract

Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene that disrupt the open reading frame and thus prevent production of functional dystrophin proteins. Recent advances in DMD treatment, notably exon skipping and AAV gene therapy, have achieved some success aimed at alleviating the symptoms related to progressive muscle damage. However, they do not address the brain comorbidities associated with DMD, which remains a critical aspect of the disease. The mdx52 mouse model recapitulates one of the most frequent genetic pathogenic variants associated with brain involvement in DMD. Deletion of exon 52 impedes expression of two brain dystrophins, Dp427 and Dp140, expressed from distinct promoters. Interestingly, this mutation is eligible for exon skipping strategies aimed at excluding exon 51 or 53 from dystrophin mRNA. We previously showed that exon 51 skipping can restore partial expression of internally deleted yet functional Dp427 in the brain following intracerebroventricular (ICV) injection of antisense oligonucleotides (ASO). This was associated with a partial improvement of anxiety traits, unconditioned fear response, and Pavlovian fear learning and memory in the mdx52 mouse model. In the present study, we investigated in the same mouse model the skipping of exon 53 in order to restore expression of both Dp427 and Dp140. However, in contrast to exon 51, we found that exon 53 skipping was particularly difficult in mdx52 mice and a combination of multiple ASOs had to be used simultaneously to reach substantial levels of exon 53 skipping, regardless of their chemistry (tcDNA, PMO, or 2′MOE). Following ICV injection of a combination of ASO sequences, we measured up to 25% of exon 53 skipping in the hippocampus of treated mdx52 mice, but this did not elicit significant protein restoration. These findings indicate that skipping mouse dystrophin exon 53 is challenging. As such, it has not yet been possible to answer the pertinent question whether rescuing both Dp427 and Dp140 in the brain is imperative to more optimal treatment of neurological aspects of dystrophinopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines11123243

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. Colombo, 2017, Assessing Mental Health in Boys with Duchenne Muscular Dystrophy: Emotional, Behavioural and Neurodevelopmental Profile in an Italian Clinical Sample, Eur. J. Paediatr. Neurol., 21, 639, 10.1016/j.ejpn.2017.02.007 · DOI · Paper page
  2. Hinton, 2009, Association of Autistic Spectrum Disorders with Dystrophinopathies, Pediatr. Neurol., 41, 339, 10.1016/j.pediatrneurol.2009.05.011 · DOI
  3. Maresh, 2023, Startle Responses in Duchenne Muscular Dystrophy: A Novel Biomarker of Brain Dystrophin Deficiency, Brain, 146, 252, 10.1093/brain/awac048 · DOI
  4. Ricotti, 2016, Neurodevelopmental, Emotional, and Behavioural Problems in Duchenne Muscular Dystrophy in Relation to Underlying Dystrophin Gene Mutations, Dev. Med. Child Neurol., 58, 77, 10.1111/dmcn.12922 · DOI · Paper page
  5. Mullard, 2023, FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy, despite Internal Objections, Nat. Rev. Drug Discov., 22, 610, 10.1038/d41573-023-00103-y · DOI
  6. Beroud, 2007, Multiexon Skipping Leading to an Artificial DMD Protein Lacking Amino Acids from Exons 45 through 55 Could Rescue up to 63% of Patients with Duchenne Muscular Dystrophy, Hum. Mutat., 28, 196, 10.1002/humu.20428 · DOI · Paper page
  7. Bladen, 2015, The TREAT-NMD DMD Global Database: Analysis of More than 7000 Duchenne Muscular Dystrophy Mutations, Hum. Mutat., 36, 395, 10.1002/humu.22758 · DOI · Paper page
  8. Araki, 1997, Targeted Disruption of Exon 52 in the Mouse Dystrophin Gene Induced Muscle Degeneration Similar to That Observed in Duchenne Muscular Dystrophy, Biochem. Biophys. Res. Commun., 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
  9. Felisari, 2000, Loss of Dp140 Dystrophin Isoform and Intellectual Impairment in Duchenne Dystrophy, Neurology, 55, 559, 10.1212/WNL.55.4.559 · DOI
  10. Hendriksen, 2020, ENMC 249th workshop study group 249th ENMC International Workshop: The Role of Brain Dystrophin in Muscular Dystrophy: Implications for Clinical Care and Translational Research, Hoofddorp, The Netherlands, November 29th-December 1st 2019, Neuromuscul. Disord., 30, 782, 10.1016/j.nmd.2020.08.357 · doi:10.1016/j.nmd.2020.08.357
  11. 2023, Global Prevalence of Intellectual Developmental Disorder in Dystrophinopathies: A Systematic Review and Meta-Analysis, Dev. Med. Child. Neurol., 65, 734, 10.1111/dmcn.15481 · DOI
  12. Taylor, P.J., Betts, G.A., Maroulis, S., Gilissen, C., Pedersen, R.L., Mowat, D.R., Johnston, H.M., and Buckley, M.F. (2010). Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy. PLoS ONE, 5. · DOI · Paper page
  13. Saoudi, 2023, Partial Restoration of Brain Dystrophin by Tricyclo-DNA Antisense Oligonucleotides Alleviates Emotional Deficits in Mdx52 Mice, Mol. Ther. Nucleic Acids, 32, 173, 10.1016/j.omtn.2023.03.009 · DOI
  14. Saoudi, A., Fergus, C., Gileadi, T., Montanaro, F., Morgan, J.E., Kelly, V.P., Tensorer, T., Garcia, L., Vaillend, C., and Muntoni, F. (2023). Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models. Cells, 12. · DOI
  15. Aoki, 2012, Bodywide Skipping of Exons 45-55 in Dystrophic Mdx52 Mice by Systemic Antisense Delivery, Proc. Natl. Acad. Sci. USA, 109, 13763, 10.1073/pnas.1204638109 · DOI · Paper page
  16. Blau, 1983, Cytoplasmic Activation of Human Nuclear Genes in Stable Heterocaryons, Cell, 32, 1171, 10.1016/0092-8674(83)90300-8 · DOI · Paper page
  17. Relizani, 2022, Palmitic Acid Conjugation Enhances Potency of Tricyclo-DNA Splice Switching Oligonucleotides, Nucleic Acids Res., 50, 17, 10.1093/nar/gkab1199 · DOI
  18. Paxinos, G., and Franklin, K.B.J. (2001). The Mouse Brain in Stereotaxic Coordinates, Academic Press. [2nd ed.].
  19. Aupy, 2020, Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in Mdx52 Mice, Mol. Ther. Methods Clin. Dev., 17, 1037, 10.1016/j.omtm.2020.04.025 · DOI · Paper page
  20. Mitrpant, 2009, Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping, Mol. Ther., 17, 1418, 10.1038/mt.2009.49 · DOI
  21. Saoudi, 2021, Emotional Behavior and Brain Anatomy of the Mdx52 Mouse Model of Duchenne Muscular Dystrophy, Dis. Model. Mech., 14, dmm049028, 10.1242/dmm.049028 · DOI · Paper page
  22. Kaman, 2006, Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons, Mol. Ther., 14, 401, 10.1016/j.ymthe.2006.02.022 · DOI
  23. Kim, 2022, Exon-Skipping Antisense Oligonucleotides for Cystic Fibrosis Therapy, Proc. Natl. Acad. Sci. USA, 119, e2114858118, 10.1073/pnas.2114858118 · DOI
  24. Echigoya, 2015, Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45-55 with a Cocktail of Vivo-Morpholinos in Mdx52 Mice, Mol. Ther. Nucleic Acids, 4, e225, 10.1038/mtna.2014.76 · DOI
  25. Echigoya, 2019, Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene, Mol. Ther., 27, 2005, 10.1016/j.ymthe.2019.07.012 · DOI
  26. Spitali, 2013, DMD Transcript Imbalance Determines Dystrophin Levels, FASEB J., 27, 4909, 10.1096/fj.13-232025 · DOI · Paper page
  27. Hiller, 2020, Premature Termination Codons in the DMD Gene Cause Reduced Local mRNA Synthesis, Proc. Natl. Acad. Sci. USA, 117, 16456, 10.1073/pnas.1910456117 · DOI
  28. Clemens, 2020, Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial, JAMA Neurol., 77, 982, 10.1001/jamaneurol.2020.1264 · DOI · Paper page
  29. Kudoh, 2005, A New Model Mouse for Duchenne Muscular Dystrophy Produced by 2.4 Mb Deletion of Dystrophin Gene Using Cre-loxP Recombination System, Biochem. Biophys. Res. Commun., 328, 507, 10.1016/j.bbrc.2004.12.191 · DOI · Paper page
  30. Doorenweerd, 2017, Timing and Localization of Human Dystrophin Isoform Expression Provide Insights into the Cognitive Phenotype of Duchenne Muscular Dystrophy, Sci. Rep., 7, 12575, 10.1038/s41598-017-12981-5 · DOI · Paper page
  31. Hashimoto, Y., Kuniishi, H., Sakai, K., Fukushima, Y., Du, X., Yamashiro, K., Hori, K., Imamura, M., Hoshino, M., and Yamada, M. (2022). Brain Dp140 Alters Glutamatergic Transmission and Social Behaviour in the Mdx52 Mouse Model of Duchenne Muscular Dystrophy. Prog. Neurobiol., 216. · DOI · Paper page

Cited by

See all 13

Metadata

Authors
Doisy, M., Vacca, O., Fergus, C., Gileadi, T., Verhaeg, M., Saoudi, A., Tensorer, T., Garcia, L., Kelly, V. P., Montanaro, F., Morgan, J. E., van Putten, M., Aartsma-Rus, A., Vaillend, C., Muntoni, F., & Goyenvalle, A.
Affiliations
  • Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France
  • School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland
  • Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, 30 Guildford Street, London WC1N 1EH, UK
  • Department of Human Genetics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands
  • SQY Therapeutics-Synthena, UVSQ, 78180 Montigny le Bretonneux, France
  • Université Paris-Saclay, CNRS, Institut des Neurosciences Paris-Saclay, 91400 Saclay, France
Venue
Biomedicines
Publisher
MDPI AG
Published
2023-12-07
Volume
11
Issue
12
Pages
3243
ISSN
2227-9059
Cited by
13
References
0
Language
en
Funders
European Union (847826)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model. https://app.cochat.ai/papers/10.3390/biomedicines11123243
The paper
Doisy, M., Vacca, O., Fergus, C., Gileadi, T., Verhaeg, M., Saoudi, A., Tensorer, T., Garcia, L., Kelly, V. P., Montanaro, F., Morgan, J. E., van Putten, M., Aartsma-Rus, A., Vaillend, C., Muntoni, F., & Goyenvalle, A. (2023). Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model. Biomedicines. https://doi.org/10.3390/biomedicines11123243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.